Epirubicin

證據等級: L5

預測適應症: 10 個

Epirubicin: From Breast Cancer to Primary Pulmonary Lymphoma

One-Sentence Summary

Epirubicin is an anthracycline cytotoxic agent widely used internationally in combination chemotherapy regimens for breast cancer, gastric cancer, and various other malignancies, though it is not currently registered on the Australian Register of Therapeutic Goods (ARTG). The TxGNN model predicts it may be effective for Primary Pulmonary Lymphoma, with 0 registered clinical trials and 9 publications (predominantly indirect evidence from related B-cell lymphoma settings) currently supporting this direction. Given the rarity of the condition and absence of direct clinical evidence, this prediction remains at research hypothesis stage.

Quick Overview

Item	Content
Original Indication	Breast cancer; gastric cancer; other solid tumours (international use — no TGA registration identified)
Predicted New Indication	Primary Pulmonary Lymphoma
TxGNN Prediction Score	99.71%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on well-established pharmacology, Epirubicin (4’-epidoxorubicin) is a semi-synthetic anthracycline antibiotic and structural epimer of doxorubicin. It exerts its antitumour effect primarily through DNA intercalation and inhibition of Topoisomerase II, blocking DNA strand religation, arresting replication and transcription, and triggering apoptosis. These actions are cell-cycle non-specific and most pronounced in rapidly dividing cells that overexpress Topoisomerase IIα — a hallmark of aggressive B-cell malignancies.

Primary pulmonary lymphoma — particularly MALT (mucosa-associated lymphoid tissue) lymphoma and primary pulmonary diffuse large B-cell lymphoma (DLBCL) — are B-cell lymphomas known to be anthracycline-sensitive. Anthracycline-containing regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) remain the standard of care for aggressive B-cell lymphomas, and Epirubicin has been used as an anthracycline substitute in analogous CHOP-E (Epirubicin-substituted CHOP), CEV (cyclophosphamide, Epirubicin, vincristine), and other lymphoma regimens. The mechanistic basis underpinning the TxGNN prediction is therefore biologically plausible.

However, primary pulmonary lymphoma is an exceedingly rare entity (estimated incidence < 0.5% of primary lung malignancies), and no clinical trials have evaluated Epirubicin specifically in this setting. The supporting literature is entirely indirect — comprising general B-cell lymphoma treatment studies, case reports of pulmonary or pleural lymphoma, and Hodgkin’s lymphoma regimens incorporating Epirubicin. Direct comparative evidence between Epirubicin and doxorubicin (the standard anthracycline in R-CHOP) for pulmonary lymphoma is absent.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1866500	1991	Case Series / Clinical Report	Rev Invest Clin	Primary non-Hodgkin’s lymphoma of the lung — atypical presentation with haemorrhagic pleural effusion in right lower lobe; lymphoid atypical cells confirmed by electron microscopy; patient treated with combination chemotherapy
36237246	2022	Case Report	Transl Cancer Res	First reported case of pleural MALT lymphoma in China — highlights diagnostic difficulty and high misdiagnosis risk for primary pulmonary/pleural B-cell lymphoma; underscores unmet need for evidence-based treatment guidance
39192408	2024	Retrospective Cohort	Zhongguo Shi Yan Xue Ye Xue Za Zhi	Single-centre retrospective analysis of primary extranodal DLBCL in the rituximab era; identifies clinical features and prognostic factors relevant to extranodal (including pulmonary) DLBCL management
7686469	1993	Review	Drugs	Comprehensive pharmacodynamic and clinical review of Epirubicin — documents equivalent efficacy to doxorubicin across multiple malignancies including lymphomas, with a more favourable cardiac toxicity profile
40728626	2025	Clinical Study	Ann Hematol	Pola-R-CHP effective in Polarix trial-ineligible DLBCL patients (n=117); provides contemporary context for anthracycline-containing first-line regimens in DLBCL including extranodal presentations
16428496	2006	Retrospective Study	Clin Cancer Res	MOPPEBVCAD regimen (containing epidoxorubicin/Epirubicin) with limited radiotherapy in advanced Hodgkin’s lymphoma — 10-year results with acceptable late toxicity; demonstrates Epirubicin activity in lymphoma regimens
10526668	1999	Clinical Study	Cancer J Sci Am	VEBEP (containing Epirubicin) plus involved-field radiotherapy in advanced Hodgkin’s disease — pilot study demonstrating efficacy and tolerability
8386780	1993	Case Report	Jpn J Clin Hematol	Malignant lymphoma (lymphoblastic) developing after resection and chemotherapy for small cell lung carcinoma — illustrates diagnostic complexity at the intersection of lung malignancy and lymphoma
7525516	1994	Clinical Study	Int J Radiat Oncol Biol Phys	Extended-field radiotherapy in Stage IA-IIA favourable Hodgkin’s disease — long-term outcomes data providing historical comparator context for lymphoma management

Australia Market Information

Epirubicin is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no ARTG entries for this drug. Any clinical use in Australia would require access through the TGA Special Access Scheme (SAS Category B or C) or an Authorised Prescriber pathway. Clinicians should consult international Product Information (e.g., EMA SmPC or FDA prescribing information) in the absence of a TGA-approved PI.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Anthracycline antibiotic class (4’-epimer of doxorubicin; DNA intercalator and Topoisomerase II poison)
Myelosuppression Risk	High — leucopenia and neutropenia are dose-limiting toxicities; nadir typically at days 10–14; thrombocytopenia and anaemia also occur; G-CSF support often required at higher doses
Emetogenicity Classification	Moderate to high (consistent with other anthracyclines; antiemetic prophylaxis with 5-HT₃ antagonist ± NK₁ antagonist recommended)
Monitoring Items	FBC with differential and platelets prior to each cycle; LVEF assessment (echocardiogram or MUGA scan) at baseline, after 300 mg/m² and 450 mg/m², and periodically thereafter; cumulative lifetime dose tracking (cardiotoxicity risk rises substantially above 900 mg/m²); liver function tests (Epirubicin is hepatically metabolised; dose reduction required for hepatic impairment); renal function
Handling Protection	Must follow cytotoxic drug handling regulations (SHPA/ISOPP standards) — protective gloves, closed-system drug transfer devices (CSTD), and biological safety cabinet required for preparation; vesicant: extravasation can cause severe tissue necrosis requiring specialist management

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. As Epirubicin is not registered in Australia, clinicians should consult the relevant international PI/SmPC. Key safety areas of particular relevance include:

Cardiotoxicity: Dose-dependent, potentially irreversible cardiomyopathy and congestive heart failure — risk increases with cumulative dose and prior/concurrent anthracycline or radiation exposure to the mediastinum
Secondary leukaemia: Epirubicin-based regimens carry a documented risk of therapy-related AML/MDS (t-AML/t-MDS), particularly when combined with alkylating agents; this risk increases with cumulative dose and co-administration of cyclophosphamide (see PMID 15961765)
Vesicant properties: Severe local tissue necrosis on extravasation; anthracycline extravasation kits and dexrazoxane access should be confirmed prior to administration

Conclusion and Next Steps

Decision: Hold

Rationale: Primary pulmonary lymphoma is an extremely rare malignancy with no registered clinical trials evaluating Epirubicin specifically in this indication; all available supporting literature is indirect (general B-cell lymphoma or Hodgkin’s lymphoma studies), and Epirubicin carries a significant safety burden — including cardiotoxicity and secondary leukaemia risk — that cannot be adequately characterised in the absence of disease-specific evidence. Furthermore, Epirubicin is not registered in Australia, creating additional regulatory and practical barriers to clinical use.

To proceed, the following is needed:

Systematic literature review of anthracycline-containing regimens (R-CHOP and variants) specifically in primary pulmonary MALT lymphoma and primary pulmonary DLBCL, to determine whether doxorubicin-to-Epirubicin substitution is supported
Mechanism of action (MOA) data confirming Topoisomerase IIα expression levels in primary pulmonary lymphoma subtypes
Prospective registry or observational data on primary pulmonary lymphoma treatment outcomes in Australia, given the absence of disease-specific RCTs globally
TGA Special Access Scheme (SAS) pre-approval pathway assessment if clinical use is being considered
Formal cardiotoxicity risk-benefit analysis, particularly given that doxorubicin (standard R-CHOP backbone) is already TGA-registered and widely available in Australia
Consultation with a haematology/oncology multidisciplinary team (MDT) with expertise in rare lymphoma subtypes prior to any clinical application

Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any clinical application. All information should be interpreted by qualified healthcare professionals in conjunction with current clinical guidelines and the patient’s individual circumstances.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.